Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Gastrointestinal tract spasm.
|
|
Dosage/Direction for Use
Adult: PO 10-20 mg tid. IM 10-20 mg 4 times daily for 1-2 days if oral therapy is temporarily impractical.
|
|
Administration
May be taken with or without food. May be taken before or after meals.
|
|
Contraindications
Obstructive diseases of the gastrointestinal tract, severe ulcerative colitis, reflux oesophagitis, unstable cardiovascular status in acute haemorrhage, glaucoma, obstructive uropathy, myasthenia gravis, salmonella dysentery. Infants (<6 months). Lactation.
|
|
Special Precautions
Patient with prostatic hypertrophy, coronary artery disease, tachyarrhythmic conditions, thyrotoxicosis, congestive heart failure, hypertension, autonomic neuropathy, mild-moderate ulcerative colitis, intestinal obstruction e.g. ileostomy or colostomy, mental illness. Renal and hepatic impairment. Children and elderly. Pregnancy. Patient Counselling This drug may cause dizziness, drowsiness or blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor anticholinergic effects (e.g. asthenia, nervousness), urinary output, gastrointestinal symptoms.
|
|
Adverse Reactions
Significant: Heat prostration, psychosis or delirium, diarrhoea.
Cardiac disorders: Tachyarrhythmia, palpitations, transient bradycardia.
Eye disorders: Mydriasis, cycloplegia, photophobia, rarely, blurred vision.
Gastrointestinal disorders: Dry mouth with difficulty swallowing and talking, dyspepsia, abdominal distension, abdominal pain, rarely, constipation, nausea, vomiting.
General disorders and administration site conditions: Malaise, fatigue.
Investigations: Decreased lactation.
Metabolism and nutrition disorders: Thirst, rarely, anorexia.
Nervous system disorders: Dizziness, rarely, sedation, headache.
Psychiatric disorders: Nervousness, insomnia, confusion, hallucinations.
Renal and urinary disorders: Rarely, dysuria.
Respiratory, thoracic and mediastinal disorders: Reduced bronchial secretions.
Skin and subcutaneous tissue disorders: Dry skin, rarely, rash.
|
|
Drug Interactions
May enhance the anticholinergic effect of tiotropium, ipratropium, glycopyrrolate, oxatomide, revefenacin. May enhance ulcerogenic effect of K citrate. Increased serum concentration of thiazide diuretics. May decrease the absorption of nitroglycerin.
|
|
CIMS Class
|
|
ATC Classification
A03AA07 - dicycloverine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.
|
